araag2/HINT huggingface dataset:
Clinical trial NCT01256450 (phase 3, status: completed)
Conditions: pain, low back pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, M54.50, M54.51, M54.59
Drugs: buprenorphine, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or non-pregnant and non-nursing female aged 18 or older

          -  History of moderate to severe chronic low back pain for ≥3 months with a pain
             intensity ≥5 [11 point numerical rating scale] reported at the open-label titration
             period Day 0/1 visit following a washout period (opioids, nonsteroidal
             anti-inflammatory drugs [NSAIDs], and muscle relaxants) of approximately 12 to 24
             hours

          -  Currently taking ≤60 mg oral morphine/day or equianalgesic dose of another opioid
             (including opioid naïve) for 1 week or longer

          -  Stable health, as determined by the Investigator, on the basis of medical history,
             physical examination, and screening laboratory results so as to comply with all study
             procedures

          -  Female subjects of childbearing potential must be using a recognized effective method
             of birth control

          -  Written informed consent obtained at Screening, prior to any procedure being performed

        Exclusion Criteria:

          -  Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute
             spinal cord compression, cauda equina compression, acute nerve root compression,
             meningitis, and discitis

          -  Surgical procedure for back pain within 2 months prior to screening or nerve/plexus
             block within 4 weeks of screening

          -  Hypokalemia or clinically unstable cardiac disease, including: unstable atrial
             fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active
             myocardial ischemia

          -  Corrected QT (QTc) interval of >450 milliseconds on the 12-lead electrocardiogram
             (ECG)

          -  History of long QT syndrome, or an immediate family member with this condition

          -  Diagnosis of moderate to severe hepatic impairment.

          -  History of severe emesis with opioids

          -  Clinically significant sleep apnea
Clinical trial NCT00537485 (phase 2/phase 3, status: completed)
Conditions: early parkinson's disease
ICD codes: G20
Drugs: spm 962, placebo
SMILES: CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic
             Criteria established by the Research Committee of MHLW-specified Intractable
             Neurodegenerative Diseases (1995)"

          2. Subject is 30 years < > 80 years at the time of informed consent

          3. Hoehn & Yahr stage 1- 3

          4. Total of each sum score of UPDRS Part 2 and 3 is over 10 at screening test

        Exclusion Criteria:

          1. Subject has previously participated in a trial with SPM 962

          2. Subject is on L-dopa treatment for total of over 6 months at the time of informed
             consent

          3. Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation,
             delirium, abnormal behavior at screening test and baseline

          4. Subject has orthostatic hypotension

          5. Subject has a history of epilepsy, convulsion and other

          6. Subject has a complication of serious cardiac disorder/arrhythmia or has the history

          7. Subject has arrhythmia and treated with class 1a anti-arrhythmic drugs (e.g.
             quinidine, procainamide etc.) or class 3 anti-arrhythmic drugs (e.g. amiodarone,
             sotalol etc.)

          8. Subject has serious ECG abnormal at screening i.e.; 1) Subject has more than 450 msec
             of QTc values both in two measurements at screening test 2) Subject has more than 470
             msec for females and more than 450 msec for males of mean QTc values of two
             measurements at baseline

          9. Subject has congenital long QT syndrome

         10. Subject has serum potassium of less than 3.5 mEq/L at screening test.

         11. Subject has total bilirubin of 3.0 mg/dL and above or AST(GOT), ALT(GPT) greater than
             2.5 times (or 100 IU/L and above) of the clinical laboratory's upper limit of the
             reference range at screening test

         12. Subject has 30 mg/dL and above of BUN or 2.0 mg/dL and above of serum creatinine at
             screening test

         13. Subject has a history of allergy to topical medicine, e.g. transdermal patch

         14. Subject is pregnant, nursing, or is child bearing potential while the trial

         15. Subject is receiving therapy with prohibited drug specified in the study protocol

         16. Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal
             tissue transplant

         17. Subject has dementia

         18. Subject is unable to give consent

         19. Subject is participating in another trial of an investigational drug or done so within
             12 weeks prior to the initial treatment

         20. Investigator judges that subject is inappropriate as a study subject with other
             reasons
Clinical trial NCT00683657 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: saxagliptin, placebo
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  ≥18- and ≤77-years-old

          -  Type 2 diabetes

          -  Taking metformin immediate release (IR) or XR ≥1500 mg for at least 8 weeks as
             monotherapy

          -  Glycosylated hemoglobin (A1C) ≥7% and ≤10%

          -  Body mass index (BMI) ≤40 kg/m2

        Exclusion Criteria:

          -  Women of childbearing potential unable or unwilling to use acceptable birth control

          -  Women who are pregnant or breastfeeding

          -  Significant cardiovascular history

          -  Active liver disease

          -  Renal impairment
Clinical trial NCT00259779 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: budesonide/formoterol, prednisolone
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with chronic obstructive pulmonary disease and an acute exacerbation

          -  After the acute treatment a simple pulmonary function test shows a value of 30%-60% of
             the predicted normal value.

          -  Patients, who, based on the clinical examination after the initial acute treatment,
             are candidates for a course of oral steroids for the treatment of acute symptoms due
             to chronic obstructive pulmonary disease

        Exclusion Criteria:

          -  Diagnosis/history of asthma

          -  Oxygen uptake (saturation) is <92% after the initial acute treatment

          -  A requirement for regular use of oxygen therapy

          -  Regular treatment with any inhaled steroid >1 000 µg/day at study entry

        Additional inclusion and exclusion criteria will be evaluated by the investigator
Clinical trial NCT00376766 (phase 3, status: terminated)
Conditions: epilepsy, drug resistant
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: levetiracetam
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Reason stopped: 
    recruitment recruitment recruitment recruitment difficulties
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age from 18 to 65

          -  Drug resistant epilepsy, partial seizure

          -  Epilepsy diagnosed for more than 2 years

          -  Epilepsy treated for more than 1 year with no change of treatment in the month before
             the enrolment

          -  Onset of cluster seizure in the 24 hours before enrolment

          -  For women : effective contraception

          -  Affiliation to the French social security

        Exclusion Criteria:

          -  Inability to tolerate levetiracetam, likely poor compliance

          -  Patient taking antiepileptic treatment (benzodiazepine) in addition to current
             treatment during the last 48h00.

          -  Patient taking 1g/day of levetiracetam with Creatinin clearance < 50ml/min

          -  Patient taking 2g/day of levetiracetam with Creatinin clearance < 80ml/min

          -  Patient taking more than 2g/day of levetiracetam

          -  Hepatic or cardiovascular pathology

          -  Progressive psychiatric pathology

          -  Degenerative neurologic disease

          -  Cluster seizure due to an acute symptomatic reason

          -  Disorder of consciousness

          -  Suspicion of status epilepticus or rapid evolution to status epilepticus

          -  Suspicion of psychogenic nonepileptic seizure

          -  Pregnant woman or nursing woman

          -  Suicidal thoughts

          -  Incapacity to give consent, minor patient
Clinical trial NCT00197197 (phase 3, status: terminated)
Conditions: hiv infection
ICD codes: Z21
Drugs: gw873140
SMILES: [H][C@@]1(NC(=O)C2(CCN(CC3=CC=C(OC4=CC=C(C=C4)C(O)=O)C=C3)CC2)N(CCCC)C1=O)[C@H](O)C1CCCCC1
Reason stopped: 
    the study was terminated due to hepatoxicity of compound
  
Eligibility criteria:

        Inclusion criteria:

          -  HIV-infected.

          -  Screening viral load at least 5000copies/mL.

          -  R5/X4-tropic virus at screening.

          -  Total prior antiretroviral experience of at least 3 months.

          -  Documented resistance to at least one drug in each of the following classes:
             nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse
             transcriptase inhibitors (NNRTI), and protease inhibitors (PI), stable antiretroviral
             regimen (or no antiretroviral treatment) for at least 4 weeks before screening.

          -  Able to receive a ritonavir-boosted protease inhibitor during treatment studies.

          -  Women of childbearing potential must use specific forms of contraception.

        Exclusion criteria:

          -  Acute laboratory abnormalities.

          -  History of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any
             chronic liver disease. Screening liver function tests will be used to determine
             eligibility.

          -  R5-tropic only.

          -  X4-tropic only.

          -  non-phenotypeable virus at screening.

          -  Changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of
             treatment study.

          -  Pregnancy or breastfeeding women.

          -  Recent participation in an experimental drug trial.

          -  Prior use of a CCR5 or CXCR4 antagonist.

          -  Significant ECG abnormalities or significant history of active pancreatitis,
             hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe
             illness.

          -  Current use of certain medications may exclude participation in this study.

          -  Additional qualifying criteria and laboratory test requirements to be assessed by
             study physician.
Clinical trial NCT01358578 (phase 3, status: completed)
Conditions: chronic plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: placebo, secukinumab (ain457), etanercept
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with chronic, plaque-type psoriasis for at least 6 months

          -  Must have moderate to severe psoriasis based on PASI greater than 12, IGA greater than
             3, and greater than 10% body surface area

          -  Must be inadequately controlled by prior treatments (topicals, phototherapy, and/or
             systemic therapies)

        Exclusion Criteria:

          -  Forms of psoriasis other than chronic, plaque-type (such as pustular, erythrodermic
             and guttate psoriasis)

          -  Drug induced psoriasis

          -  Use of other psoriasis treatments during the study

          -  Prior use of etanercept

          -  Prior use of secukinumab or any other drug that target IL-17 (interleukin 17) or the
             IL-17 receptor

          -  Pregnant or lactating women; women who do not agree to use contraception during the
             study and for 16 weeks after stopping treatment

          -  Significant medical problems such as uncontrolled high blood pressure, congestive
             heart failure, etc.

          -  History of an ongoing, chronic or recurrent infection or evidence of tuberculosis

          -  Allergy to rubber or latex

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00354081 (phase 3, status: completed)
Conditions: coronary artery disease, myocardial infarction, cerebrovascular stroke
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118, I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: folic acid, vitamin b12 (cyanocobalamin), vitamin b6 (pyridoxine), folic acid, vitamin b12 (cyanocobalamin), vitamin b6 (pyridoxine), placebo
SMILES: [C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO, CC1=C(O)C(CO)=C(CO)C=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  adults ≥ 18 years able to give informed consent

          -  patients prepared to undergo long-term follow-up

          -  patients with and without significant coronary artery disease (CAD) who have undergone
             coronary angiography just before inclusion

        Exclusion Criteria:

          -  patients who are not available for follow-up

          -  patients who have previously participated in this study

          -  patients with known alcohol abuse or serious mental illness

          -  patients with known active malignant disease

          -  patients who have undergone coronary angiography for specific reasons, i.e. assessment
             for cardiac transplantation, kidney donor, heart donor, diagnostic assessment of
             cardiomyopathy
Clinical trial NCT00000614 (phase 3, status: completed)
Conditions: cardiovascular diseases, heart diseases, peripheral vascular diseases, thromboembolism, vascular diseases, venous thromboembolism
ICD codes: A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30, I11.0, I11.9, I27.1, I51.9, I09.9, I27.9, I01.8, I73.9, I73.89, O88.22, O88.23, O88.211, O88.212, O88.213, O88.219, I73.9, D57.03, D57.213, G46.8, I73.89, O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: warfarin
SMILES: S1SSSSSSS1
Eligibility criteria:

        Patients with venous thromboembolism, including patients with factor V Leiden. Patients had
        completed prescribed anticoagulation therapy within the last two years before the trial and
        were not currently on anticoagulation therapy.
Clinical trial NCT00617669 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: docetaxel, zd4054, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=C1)C1=NN=CO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Patients who answer TRUE to the following criteria may be eligible to participate in this
        trial.

          -  Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has
             spread to the bone (bone metastasis)

          -  Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment

          -  Currently receiving treatment with surgical or medical castration

        Exclusion Criteria:

        Patients who answer TRUE to the following ARE NOT eligible to participate in this trial.

          -  Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior
             targeted cancer therapies are permitted if received during a previous clinical trial.

          -  Suffering from heart failure or had a myocardial infarction within last 6 months

          -  A history of epilepsy or seizures
Clinical trial NCT01189890 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate, glimepiride, placebo to sitagliptin, placebo to glimepiride
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion Criteria

          -  Diagnosis of type 2 diabetes mellitus

        Exclusion Criteria

          -  History of type 1 diabetes mellitus

          -  Has undergone a surgical procedure within the prior 4 weeks.

          -  Current participation in, or has participated, in another study with an
             investigational device or compound, with the prior 12 weeks, and/or is not willing to
             refrain from participating in any other study while participating in this study

          -  Hypersensitivity or contraindication to any sulfonylurea (e.g., glimepiride)
             medication

          -  Has been on an investigational or approved dipeptidyl peptidase-4 (DPP-4) inhibitor
             agent (e.g., sitagliptin, saxagliptin)

          -  Presence of human immunodeficiency virus (HIV)

          -  Current participation in a weight loss program or is receiving weight loss medication

          -  History of blood disorder, certain cancers, heart, liver or kidney disease

          -  Current or past use of recreational or illicit drugs, or a history of drug abuse or
             dependence, or increased alcohol consumption
Clinical trial NCT00486759 (phase 3, status: terminated)
Conditions: b-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bevacizumab, rituximab, chop, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    due to an unfavorable benefit/risk ratio.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, ≥ 18 and < 80 years of age.

          -  CD20-positive diffuse large B-cell lymphoma.

          -  Low-intermediate, high-intermediate, or high risk disease and/or bulky tumor (largest
             diameter ≥ 7.5 cm).

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

        Exclusion Criteria:

          -  Prior treatment for diffuse large B-cell lymphoma.

          -  Types of non-Hodgkin's lymphoma other than diffuse large B-cell lymphoma (DLBCL).

          -  Central nervous system (CNS) involvement of lymphoma.
Clinical trial NCT01783548 (phase 3, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: bdp nasal aerosol, placebo
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects 4 to 11 years of age, inclusive, as of the Screening Visit
             (SV).

          -  A documented history of PAR to a relevant perennial allergen for a minimum of 12
             months (6 months for subjects 4 to 5 years of age) immediately preceding the study
             Screening Visit (SV).

          -  A demonstrated sensitivity to at least one allergen known to induce PAR through a
             standard skin prick test.

          -  Other criteria apply.

        Exclusion Criteria:

          -  History of physical findings of nasal pathology, including nasal polyps or other
             clinically significant respiratory tract malformations, recent nasal biopsy, nasal
             trauma (e.g., nasal piercing) or surgery, atrophic rhinitis, or rhinitis medicamentosa
             (all within the last 60 days prior to the Screening Visit [SV]).

          -  History of a respiratory infection or disorder (including, but not limited to
             bronchitis, pneumonia, chronic sinusitis or influenza) within the 14 days preceding
             the Screening Visit (SV), or development of a respiratory infection during the Run-In
             Period.

          -  Active asthma requiring treatment with inhaled or systemic corticosteroids and/or
             routine use of beta-agonists and any controller drug (e.g., theophylline, leukotriene
             antagonists). History of intermittent use (less than or equal to 3 uses per week) of
             inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable.

          -  Have any of the following conditions that are judged by the investigator to be
             clinically significant and/or affect the subject's ability to participate in the
             clinical trial.

          -  Other criteria apply.
Clinical trial NCT01152190 (phase 3, status: completed)
Conditions: benign prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: tadalafil, placebo
SMILES: [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria

          -  Present with benign prostatic hyperplasia

          -  Provide signed informed consent at the screening

          -  Agree not to use other treatment for Benign Prostatic Hyperplasia, Erectile
             Dysfunction or Overactive Bladder (including herbal treatments) during the study

        Exclusion Criteria

          -  Have prostatic cancer or are being treated for cancer.

          -  Any condition that may negatively influence the transrectal ultrasound.

          -  Are being treated for heart disease with any drug that is called a nitrate (for
             example, nitroglycerin).

          -  Any evidence of moderate to severe cardiac disease

          -  Have had any of the following in the past 90 days: chest pain (called unstable angina
             or angina) that requires treatment, heart attack also known as myocardial infarction,
             heart bypass surgery (called coronary artery bypass graft surgery), had a procedure to
             open up blood vessels in the heart know as angioplasty or stent placement
             (percutaneous coronary intervention), positive cardiac stress test without effective
             cardiac intervention.

          -  Have very high or very low blood pressure.

          -  Have uncontrolled diabetes.

          -  Have certain problems with your kidneys, liver, or nervous system.